Wanted pages
From Glioblastoma Treatments
Jump to navigationJump to search
List of non-existing pages with the most links to them, excluding pages which only have redirects linking to them. For a list of non-existent pages that have redirects linking to them, see the list of broken redirects.
Showing below up to 50 results in range #301 to #350.
- Phase II and III for metronomic dosing schedules (1 link)
- Phase II clinical trials and retrospective studies for GBM (1 link)
- Phase I pharmacodynamics trial at Washington University, ongoing research (1 link)
- Potential side effects are not well-documented due to its primary use in research; however, as with many natural compounds, potential for gastrointestinal upset exists. (1 link)
- Preclinical (rodent studies) (1 link)
- Preclinical and early clinical trials (e.g., prostate cancer study at UCLA) (1 link)
- Preclinical studies and a retrospective safety and tolerability study in glioma patients (1 link)
- Preclinical studies and observational studies in animals and humans (1 link)
- Preclinical studies and some clinical trials (1 link)
- Preliminary data suggest potential improvement in overall survival, but specific figures for GBM are under investigation (1 link)
- Preliminary data suggest potential improvement in progression-free survival, but specific figures for GBM are under investigation (1 link)
- Preliminary data suggests a potential role in slowing glioblastoma progression, but more studies are needed. (1 link)
- Primary GBM: median survival of 5.9 months; Secondary GBM: median survival of 11.2 months (1 link)
- Progression-free survival of 6-12 months reported in some studies (1 link)
- Prospective study shows median PFS of 10.5 months (1 link)
- ReACT trial showed a 6-month PFS of 28% for the rindopepimut group compared to 16% for the control (1 link)
- Reported side effects are minimal, including potential site reactions and flu-like symptoms. Few serious adverse events related to the vaccine have been reported. (1 link)
- Research ongoing (1 link)
- Resveratrol is being studied for its potential anti-cancer properties in preclinical and early clinical trials, focusing on its ability to modulate various signaling pathways involved in cell proliferation and survival. (1 link)
- Retrospective Studies (1 link)
- Retrospective studies and a prospective phase II trial (1 link)
- Retrospective studies and laboratory research (1 link)
- Reviewed in recent meta-analyses and studies (1 link)
- Sativex combined with dose-intense temozolomide: Median survival exceeded 550 days (over 18 months) (1 link)
- Shows potential for treating recurrent GBM, especially in specific genetic profiles like unmethylated MGMT promoter. Comparative mOS suggests potential improvement over lomustine. (1 link)
- Shows promise for targeted radiation delivery to tumor cells with potential for sparing normal tissue and reducing side effects, but more research is needed for a definitive assessment (1 link)
- Significant in the context of preliminary findings from retrospective studies (1 link)
- Significant reduction in tumor size noted, durability of response under investigation (1 link)
- Silibinin (Silymarin) (1 link)
- Skin irritation at the application site, mild to moderate headache, fatigue (1 link)
- Some retrospective analyses indicate extended survival in glioblastoma patients using COC Protocol alongside standard treatments. (1 link)
- Specifics depend on individual drugs; can include rash, diarrhea, and potential infusion reactions (1 link)
- Stage 1 median overall survival was 11.0 months with a 12-month OS rate of 44%. Stage 2 showed a median OS of 11.7 months with a 12-month OS rate of 50%, suggesting an improvement over historical data. (1 link)
- Standard progression statistics for GBM (1 link)
- Standard treatment: median survival of 16.1 months (1 link)
- Standard treatments offer a median PFS of about 6.9 months (1 link)
- Studies suggest PPIs may improve progression-free survival in cancer treatment (1 link)
- Studies suggest a potential improvement in overall survival, with some reports indicating up to 20-24 months in certain patient populations (1 link)
- Studies suggest improved survival rates in various cancers when added to chemotherapy; specific glioma-related outcomes are less clear (1 link)
- Study-specific; one phase 2 trial reported no significant difference in PFS with the addition of celecoxib (1 link)
- The COC Protocol is being evaluated for its impact on cancer progression, particularly in glioblastoma. Retrospective studies suggest potential survival benefits, and individual drugs within the protocol have been studied for their anti-cancer effects. (1 link)
- The combination of CPT-11 with agents like Bevacizumab and Temozolomide has shown potential in treating recurrent malignant gliomas, suggesting a meaningful clinical benefit in this challenging patient population. (1 link)
- The primary advantage of GKRS for GBM lies in its lower toxicity profile, offering a safer treatment option for select patients without compromising on the progression-free survival (PFS) or overall survival (OS) rates. (1 link)
- Transient, low-grade local reactions; overall well-tolerated (1 link)
- Tumor Treating Fields (TTFields) (1 link)
- Typically around 6-7 months for standard GBM treatments. (1 link)
- Typically less than 7 months for newly diagnosed GBM under standard treatment (1 link)
- Under investigation; initial results indicate possible benefits in slowing disease progression (1 link)
- Under investigation; preliminary results suggest potential for improved survival in glioblastoma patients. (1 link)
- Under investigation; shown to have anti-cancer effects in laboratory studies (1 link)
